文献速递免疫规划

重组恶性疟原虫AMA1-DiCo疟疾疫苗分别以GLA-SE或氢氧化铝佐剂在欧洲和非洲成人中的安全性与免疫原性:一项1a/1b期随机双盲多中心试验

Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
PubMed 文献 · Vaccine · 2017-09-22

本研究为1a/1b期随机双盲多中心试验,法国健康成人分别接受AMA1-DiCo/氢氧化铝(n=15)或AMA1-DiCo/GLA-SE(n=15),安全性评估后选择GLA-SE在布基纳法索健康成人中开展1b期试验(疫苗组n=18,安慰剂组n=18)。AMA1-DiCo(50µg)于基线、第4周和第26周肌内注射。疫苗无论何种佐剂均安全耐受,GLA-SE诱导的IgG应答似乎比氢氧化铝更强。

要点

  • AMA1-DiCo疫苗分别以氢氧化铝或GLA-SE为佐剂在法国成人中均安全且耐受良好。
  • 欧洲志愿者中,针对三种抗原的IgG较基线升高倍数在氢氧化铝组约100倍、GLA-SE组约200-300倍。
  • 非洲志愿者免疫后IgG水平超过欧洲志愿者观察值,高出4倍,且第三次免疫后26周仍高于基线。

核心结论

  • AMA1-DiCo疫苗无论使用何种佐剂均安全且有免疫原性,但GLA-SE在诱导IgG应答方面似乎比氢氧化铝更强。

研究设计与样本

  • 1a/1b期随机双盲多中心试验,法国健康成人接受AMA1-DiCo/氢氧化铝(n=15)或AMA1-DiCo/GLA-SE(n=15)。
  • 安全性评估后选择GLA-SE开展1b期试验,布基纳法索健康成人接受AMA1-DiCo/GLA-SE(n=18)或安慰剂(n=18)。
  • AMA1-DiCo(50µg)于基线、第4周和第26周经肌内途径给药。

主要发现

  • AMA1-DiCo无论以氢氧化铝还是GLA-SE为佐剂均安全且耐受良好。
  • 欧洲志愿者中,针对三种抗原的IgG较基线升高倍数在氢氧化铝组约100倍,在GLA-SE组约200-300倍。
  • 非洲志愿者免疫后IgG水平超过欧洲志愿者观察值,高出4倍。
  • 在欧洲和非洲志愿者中,第三次免疫后26周时DiCo特异性IgG仍高于基线水平。
  • 诱导的抗体可与来自不同虫株的全虫体发生反应。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Plasmodium falciparum Apical Membrane Antigen 1 Diversity Covering (PfAMA1-DiCo) candidate vaccine is a formulation of three recombinant variants of AMA1 designed to provide broader protection against parasites with varying AMA1 sequences. METHODS: In this staggered phase Ia/Ib randomized, double blind trial, healthy French adults received AMA1-DiCo with either Alhydrogel® (n=15) or GLA-SE (n=15). Following a safety assessment in French volunteers, GLA-SE was chosen for the phase Ib trial where healthy Burkinabe adults received either AMA1-DiCo/GLA-SE (n=18) or placebo (n=18). AMA1-DiCo (50µg) was administered intramuscularly at baseline, Week 4 and 26. RESULTS: AMAI-DiCo was safe, well tolerated either with Alhydrogel® or GLA-SE. In European volunteers, the ratios of IgG increase from baseline were about 100 fold in Alhydrogel® group and 200-300 fold in GLA-SE group for the three antigens. In African volunteers, immunization resulted in IgG levels exceeding those observed for the European volunteers with a 4-fold increase. DiCo-specific IgG remained higher 26weeks after the third immunization than at baseline in both European and African volunteers. Induced antibodies were reactive against whole parasite derived from different strains. CONCLUSION: AMA1-DiCo vaccine was safe and immunogenic whatever the adjuvant although GLA-SE appeared more potent than Alhydrogel® at inducing IgG responses. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov NCT02014727; PACTR201402000719423.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sirima SB, Durier C, Kara L, et al. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial. Vaccine. 2017. PMID: 28947345. doi:10.1016/j.vaccine.2017.09.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。